报价延迟最少15分钟:2026/03/10 00:31 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
376.97 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
14.23/22.72
|
|
企业价值
249.21B
|
| 资产负债 |
|
每股账面净值
16.06
|
| 现金流量 |
|
现金流量率
0.05
|
| 损益表 |
|
收益
36.75B
|
|
每股收益
49.78
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introducedits first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgenalso has a growing biosimilar portfolio. |
